BOCOM INTL: Maintains Hutchmed (China) 'Buy' rating, Target Price raised to 44 HKD.

BOCOM INTL released a research report stating that it maintains a "Buy" rating for Hutchmed (China) (00013), believing that the transaction conditions are reasonable and favorable for the company's long-term development. The earnings forecast has been adjusted, and the DCF Target Price has been raised to 44 Hong Kong dollars. The company has made continuous key progress in the development of pipelines in the mid to late stage, with relevant catalysts to look forward to in 2025, including: 1) Based on the success of the SAVANNAH study, partner AstraZeneca will soon submit the first overseas NDA for Savolitinib to the FDA (2/3 LMET abnormal treatment-resistant NSCLC); 2) China Phase III SACHI study.

Sina Hong Kong Stocks20:39 ET

U.S. stock market close: Inflation concerns lead to a decline in all indexes, NVIDIA fell 6% after reaching a new high.

① The Nasdaq China Golden Dragon Index fell by 0.2%, with China Concept Stocks showing mixed results; ② NVIDIA launched its personal computing product Project DIGITS; ③ XPENG Huaitian: Flying cars will be mass-produced and delivered in 2026; ④ Vaccine stocks soared, with Moderna rising nearly 12% and Novavax increasing by nearly 11%.

cls.cn17:04 ET

J&J Lung Cancer Treatment Extends Lives Versus AstraZeneca Drug | NYSE:JNJ

Proactive Investors13:33 ET

Unusual Options Activity: BP, TPR and Others Attract Market Bets, BP V/OI Ratio Reaches 156.3

Moomoo News13:30 ET

J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC

Seeking AlphaJan 7 10:27 ET

Johnson & Johnson Reports 'Statistically Significant' Data From Trial of Rybrevant, Lazcluze Combination to Treat Lung Cancer

MT NewswiresJan 7 08:55 ET